^
Association details:
| Biomarker: | UGT1A1∗1 |
|---|---|
| Cancer: | Colorectal Cancer |
| Regimen: | (capecitabine + irinotecan) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer
Published date:
10/29/2020
Excerpt:
...the experimental group: radiation with capecitabine combined with weekly irinotecan 80 mg/m2 for patients with UGT1A1*1*1 or 65 mg/m2 for patients with UGT1A1*1*28, followed by irinotecan and capecitabine....The pCR rates were 15% (n = 27 of 178) and 30% (n = 53 of 178) in the control and experimental groups (risk ratio, 1.96; 95% CI, 1.30 to 2.97; P = .001)....Adding irinotecan guided by UGT1A1 genotype to capecitabine-based neoadjuvant chemoradiotherapy significantly increased complete tumor response in Chinese patients.
DOI:
10.1200/JCO.20.01932
Trial ID:
